Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Changes in Care After Implementing a Multifaceted Intervention to Improve Preventive Cardiology Practice in Rheumatoid Arthritis.

Majka DS, Lee JY, Peprah YA, Lipiszko D, Friesema E, Ruderman EM, Persell SD.

Am J Med Qual. 2019 May/Jun;34(3):276-283. doi: 10.1177/1062860618798719. Epub 2018 Sep 9.

PMID:
30196708
2.

Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis.

Mandelin AM 2nd, Homan PJ, Shaffer AM, Cuda CM, Dominguez ST, Bacalao E, Carns M, Hinchcliff M, Lee J, Aren K, Thakrar A, Montgomery AB, Bridges SL Jr, Bathon JM, Atkinson JP, Fox DA, Matteson EL, Buckley CD, Pitzalis C, Parks D, Hughes LB, Geraldino-Pardilla L, Ike R, Phillips K, Wright K, Filer A, Kelly S, Ruderman EM, Morgan V, Abdala-Valencia H, Misharin AV, Budinger GS, Bartom ET, Pope RM, Perlman H, Winter DR.

Arthritis Rheumatol. 2018 Jun;70(6):841-854. doi: 10.1002/art.40453. Epub 2018 May 3.

3.

Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance.

Ghosh N, Ruderman EM.

Arthritis Res Ther. 2017 Dec 22;19(1):286. doi: 10.1186/s13075-017-1493-8. Review.

4.

Standardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities.

Bacalao EJ, Greene GJ, Beaumont JL, Eisenstein A, Muftic A, Mandelin AM, Cella D, Ruderman EM.

Clin Rheumatol. 2017 Aug;36(8):1729-1736. doi: 10.1007/s10067-017-3731-5. Epub 2017 Jun 26.

PMID:
28653263
5.

Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis.

Harrold LR, Reed GW, John A, Barr CJ, Soe K, Magner R, Saunders KC, Ruderman EM, Haselkorn T, Greenberg JD, Gibofsky A, Harrington JT, Kremer JM.

Arthritis Care Res (Hoboken). 2018 Mar;70(3):379-387. doi: 10.1002/acr.23294. Epub 2018 Feb 6.

6.

Willie Sutton Was Right: It's Time to Turn to the Synovium to Drive Rheumatoid Arthritis Therapy.

Ruderman EM, Mandelin AM, Perlman HR.

J Rheumatol. 2016 Dec;43(12):2089-2091. No abstract available.

7.

Influence of Continuing Medical Education on Rheumatologists' Performance on National Quality Measures for Rheumatoid Arthritis.

Sapir T, Rusie E, Greene L, Yazdany J, Robbins ML, Ruderman EM, Carter JD, Patel B, Moreo K.

Rheumatol Ther. 2015 Dec;2(2):141-151. Epub 2015 Oct 1.

8.

A Multifaceted Intervention to Improve Influenza, Pneumococcal, and Herpes Zoster Vaccination among Patients with Rheumatoid Arthritis.

Baker DW, Brown T, Lee JY, Ozanich A, Liss DT, Sandler DS, Ruderman EM.

J Rheumatol. 2016 Jun;43(6):1030-7. doi: 10.3899/jrheum.150984. Epub 2016 Apr 15.

9.

Understanding vaccination rates and attitudes among patients with rheumatoid arthritis.

Sandler DS, Ruderman EM, Brown T, Lee JY, Mixon A, Liss DT, Baker DW.

Am J Manag Care. 2016 Mar;22(3):161-7.

10.

Natural History, Prognosis, and Socioeconomic Aspects of Psoriatic Arthritis.

Helliwell PS, Ruderman EM.

Rheum Dis Clin North Am. 2015 Nov;41(4):581-91. doi: 10.1016/j.rdc.2015.07.004. Epub 2015 Aug 24. Review.

PMID:
26476220
11.

Of Mice and Men: Defining the Role of Interleukin 17 in Rheumatoid Arthritis.

Ruderman EM.

J Rheumatol. 2015 Jul;42(7):1069-71. doi: 10.3899/jrheum.150554. Epub 2015 Jun 1. No abstract available.

PMID:
26034153
12.

Rheumatoid arthritis: IL-6 inhibition in RA--déjà vu all over again?

Ruderman EM.

Nat Rev Rheumatol. 2015 Jun;11(6):321-2. doi: 10.1038/nrrheum.2015.58. Epub 2015 Apr 28. No abstract available.

PMID:
25907702
13.

Current Practice Patterns and Educational Needs of Rheumatologists Who Manage Patients with Rheumatoid Arthritis.

Glauser TA, Ruderman EM, Kummerle D, Kelly S.

Rheumatol Ther. 2014 Dec;1(1):31-44. Epub 2014 Sep 26.

14.

The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis.

Ruderman EM.

Bull Hosp Jt Dis (2013). 2013;71 Suppl 1:S29-32. Review.

15.

Treating to target in rheumatoid arthritis - challenges and opportunities.

Ruderman EM.

Bull Hosp Jt Dis (2013). 2013;71(3):214-7. Review.

16.

Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis.

Strand V, Rao SA, Shillington AC, Cifaldi MA, McGuire M, Ruderman EM.

Arthritis Care Res (Hoboken). 2013 Aug;65(8):1299-306. doi: 10.1002/acr.21994.

17.

IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.

Woodrick RS, Ruderman EM.

Bull NYU Hosp Jt Dis. 2012;70(3):195-9. Review.

18.

Overview of safety of non-biologic and biologic DMARDs.

Ruderman EM.

Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi37-43. doi: 10.1093/rheumatology/kes283. Review.

PMID:
23221586
19.

Incorporating the treat-to-target concept in rheumatoid arthritis.

Ruderman EM, Nola KM, Ferrell S, Sapir T, Cameron DR.

J Manag Care Pharm. 2012 Nov-Dec;18(9):1-18.

20.

Defining the value of structural inhibition. Is low-dose etanercept inferior to the standard dose?

Ruderman EM.

Rheumatology (Oxford). 2012 Dec;51(12):2118-9. doi: 10.1093/rheumatology/kes263. Epub 2012 Sep 29. No abstract available.

PMID:
23024059
21.

Proceedings of the 2012 Rheumatology Winter Clinical Symposia.

Kavanaugh A, Martin G, Cush JJ, Bergman MJ, Fleischmann R, Troum OM, Strand V, Ruderman EM, Wells AF.

Semin Arthritis Rheum. 2012 Jun;41(6):923-6. doi: 10.1016/j.semarthrit.2012.03.002.

PMID:
22617482
22.

Portability of an algorithm to identify rheumatoid arthritis in electronic health records.

Carroll RJ, Thompson WK, Eyler AE, Mandelin AM, Cai T, Zink RM, Pacheco JA, Boomershine CS, Lasko TA, Xu H, Karlson EW, Perez RG, Gainer VS, Murphy SN, Ruderman EM, Pope RM, Plenge RM, Kho AN, Liao KP, Denny JC.

J Am Med Inform Assoc. 2012 Jun;19(e1):e162-9. Epub 2012 Feb 28.

23.

Interleukin 6 inhibition - RA and beyond.

Woodrick RS, Ruderman EM.

Bull NYU Hosp Jt Dis. 2011;69(3):225-9. Review.

24.

Safety of biologic therapy in rheumatoid arthritis.

Woodrick RS, Ruderman EM.

Nat Rev Rheumatol. 2011 Oct 11;7(11):639-52. doi: 10.1038/nrrheum.2011.145. Review.

PMID:
21989284
25.

More than just B-cell inhibition.

Ruderman EM, Pope RM.

Arthritis Res Ther. 2011 Aug 30;13(4):125. doi: 10.1186/ar3439.

26.

Anti-interleukin-6 therapy in rheumatoid arthritis.

Woodrick R, Ruderman EM.

Bull NYU Hosp Jt Dis. 2010;68(3):211-7. Review.

27.

Do we really need five TNF antagonists?

Ruderman EM.

Rheumatology (Oxford). 2010 Jun;49(6):1028-9. doi: 10.1093/rheumatology/keq016. Epub 2010 Feb 19. No abstract available.

PMID:
20172993
28.

Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study.

Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE, Wiesenhutter CW, Willis L, Ruderman EM, Forstot JZ, Maricic MJ, Dao KH, Pritchard CH, Fiske DN, Burch FX, Prupas HM, Anklesaria P, Heald AE.

J Rheumatol. 2010 Apr;37(4):692-703. doi: 10.3899/jrheum.090817. Epub 2009 Dec 23.

PMID:
20032102
29.

Novel TNF antagonists for the treatment of rheumatoid arthritis.

Statkute L, Ruderman EM.

Expert Opin Investig Drugs. 2010 Jan;19(1):105-15. doi: 10.1517/13543780903438559. Review.

PMID:
20001558
30.

Intracellular signal pathways: potential for therapies.

Mavers M, Ruderman EM, Perlman H.

Curr Rheumatol Rep. 2009 Oct;11(5):378-85. Review.

31.

The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophages.

Scatizzi JC, Mavers M, Hutcheson J, Young B, Shi B, Pope RM, Ruderman EM, Samways DS, Corbett JA, Egan TM, Perlman H.

Eur J Immunol. 2009 Mar;39(3):820-5. doi: 10.1002/eji.200838683.

32.
33.

Current management of rheumatoid arthritis.

Tambar S, Ruderman EM.

Manag Care Interface. 2007 Jul;20(7):18-24.

PMID:
17849729
34.

Drug Insight: abatacept for the treatment of rheumatoid arthritis.

Ruderman EM, Pope RM.

Nat Clin Pract Rheumatol. 2006 Dec;2(12):654-60. Review.

PMID:
17133250
35.

The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach.

Gordon KB, Ruderman EM.

J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S85-91. Review.

PMID:
16488334
36.

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group.

Arthritis Rheum. 2005 Oct;52(10):3279-89.

37.

Treatment advances in psoriatic arthritis.

Ruderman EM.

Curr Rheumatol Rep. 2005 Aug;7(4):313-8. Review.

PMID:
16045835
38.
39.

Current and future pharmaceutical therapy for rheumatoid arthritis.

Ruderman EM.

Curr Pharm Des. 2005;11(5):671-84. Review.

PMID:
15720281
40.

Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction.

Issa SN, Ruderman EM.

Postgrad Med. 2004 Nov;116(5):14-6, 21-4. Review.

PMID:
15580917
41.

Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist.

Ruderman EM, Tambar S.

Dermatol Clin. 2004 Oct;22(4):477-86, x. Review.

PMID:
15450343
42.

Evaluation and management of psoriatic arthritis: the role of biologic therapy.

Ruderman EM.

J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S125-32. Review.

PMID:
12894136
43.

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.

Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, Kaine JL, Ruderman EM, Coleman P, Curtis DL, Kopp EJ, Kantor SM, Waltuck J, Lindsley HB, Markenson JA, Strand V, Crawford B, Fernando I, Simpson K, Bathon JM.

Ann Intern Med. 2002 Nov 5;137(9):726-33.

PMID:
12416946
44.
45.

Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial.

Williams GW, Ettlinger RE, Ruderman EM, Hubbard RC, Lonien ME, Yu SS, Zhao W, Geis GS.

J Clin Rheumatol. 2000 Apr;6(2):65-74.

PMID:
19078452
46.

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME.

Ann Intern Med. 1999 Mar 16;130(6):478-86.

PMID:
10075615
47.

Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis.

Ruderman EM, Crawford JM, Maier A, Liu JJ, Gravallese EM, Weinblatt ME.

Br J Rheumatol. 1997 Feb;36(2):210-3.

PMID:
9133932
48.

Psychiatric diagnoses in patients with fibromyalgia: comment on the article by Aaron et al.

Ruderman EM, Golden HE.

Arthritis Rheum. 1996 Dec;39(12):2086-7. No abstract available.

PMID:
8961920
49.

N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot study.

Gravallese EM, Handel ML, Coblyn J, Anderson RJ, Sperling RI, Karlson EW, Maier A, Ruderman EM, Formelli F, Weinblatt ME.

Arthritis Rheum. 1996 Jun;39(6):1021-6.

PMID:
8651965
50.

Early murine Lyme carditis has a macrophage predominance and is independent of major histocompatibility complex class II-CD4+ T cell interactions.

Ruderman EM, Kerr JS, Telford SR 3rd, Spielman A, Glimcher LH, Gravallese EM.

J Infect Dis. 1995 Feb;171(2):362-70.

PMID:
7844373

Supplemental Content

Loading ...
Support Center